Radiation therapy in the management of patients with unresectable stage IIIA and IIIB non-small cell lung cancer.
Treatment of patients with unresectable stage IIIA and IIIB non-small cell lung cancer with conventional radiation therapy has resulted in poor local control, a high rate of systemic failure, and 5-year survival of less than 10%. Recent modification in radiation treatment planning, dose delivery, and fractionization has demonstrated significantly improved median and 2-year survival, comparable in some trials to that achieved with induction chemotherapy followed by radiation. Current trials focus on combining systemic therapy with dose-intense radiation therapy to improve with local and systemic control.
Wagner
H
H
H. Lee Moffitt Cancer Center and Research Institute, and the Department of Radiology, University of South Florida, Tampa 33612, USA.
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D015996:Survival Rate
D011838:Radiation-Sensitizing Agents